Stock Scorecard
Stock Summary for Immunome Inc (IMNM) - $9.32 as of 11/20/2024 4:13:07 PM EST
Total Score
8 out of 30
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for IMNM
Positive earnings growth | |
P/E ratio less than Industry P/E Ratio | |
P/E ratio less than Sector P/E Ratio | |
P/E ratio that is half the growth rate (or less) | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Positive net income past year and 12 trailing months | |
Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for IMNM
Revenue growing by at least 20% average per year over the last 5 years | |
Market Capitalization under 2 billion | |
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for IMNM
Declared an ex-dividend date | |
Forward annual dividend rate greater than 2 | |
Positive net cash position the past year and most recent quarter | |
Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
Current ratio most recent quarter greater than 2 | |
Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for IMNM
P/E ratio less than five-year Average P/E ratio | |
Last Price to 52 Week Low Ratio Less Than 1 | |
Total Cash Per Share > Last Day Price | |
P/S Ratio < 1 | |
P/B Ratio < 1 |
Safety Rating Criteria for IMNM (25 out of 90)
Stock Price Rating (Max of 10) | 4 |
Historical Stock Price Rating (Max of 10) | 4 |
Stock Price Trend (Max of 10) | 0 |
Book Value (Max of 10) | 3 |
Book Value to Price (Max of 10) | 0 |
Analyst Buy Ratings (Max of 5) | 4 |
Analyst Strong Buy Ratings (Max of 5) | 4 |
Dividend Yield Percentage (Max of 10) | 0 |
Operating Margin (Max of 10) | 0 |
Trading Volume (Max of 10) | 6 |
Price to Earnings (Max of 10) | 0 |
Latest News for for IMNM
Financial Details for IMNM
Company Overview |
|
---|---|
Ticker | IMNM |
Company Name | Immunome Inc |
Country | USA |
Description | Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapies for oncology and infectious diseases. The company is headquartered in Exton, Pennsylvania. |
Sector Name | LIFE SCIENCES |
Industry Name | PHARMACEUTICAL PREPARATIONS |
Most Recent Quarter | 9/30/2024 |
Next Earnings Date | N/A |
Stock Price History |
|
Last Day Price | 9.32 |
Price 4 Years Ago | 9.68 |
Last Day Price Updated | 11/20/2024 4:13:07 PM EST |
Last Day Volume | 558,663 |
Average Daily Volume | 707,199 |
52-Week High | 30.96 |
52-Week Low | 6.93 |
Last Price to 52 Week Low | 34.49% |
Valuation Measures |
|
Trailing PE | N/A |
Industry PE | 22.60 |
Sector PE | 40.32 |
5-Year Average PE | -2.74 |
Free Cash Flow Ratio | 2.42 |
Industry Free Cash Flow Ratio | 12.03 |
Sector Free Cash Flow Ratio | 27.97 |
Current Ratio Most Recent Quarter | 6.17 |
Total Cash Per Share | 3.85 |
Book Value Per Share Most Recent Quarter | 4.97 |
Price to Book Ratio | 2.73 |
Industry Price to Book Ratio | 5.31 |
Sector Price to Book Ratio | 20.88 |
Price to Sales Ratio Twelve Trailing Months | 57.86 |
Industry Price to Sales Ratio Twelve Trailing Months | 11.82 |
Sector Price to Sales Ratio Twelve Trailing Months | 7.11 |
Analyst Buy Ratings | 4 |
Analyst Strong Buy Ratings | 2 |
Share Statistics |
|
Total Shares Outstanding | 62,417,000 |
Market Capitalization | 581,726,440 |
Institutional Ownership | N/A |
Dividends |
|
Ex-Dividend Date | N/A |
Last Dividend Amount | 0.00 |
Current Dividend Amount | 0.00 |
Total Years Dividend Increasing | N/A |
Trailing Annual Dividend Rate | 0.00 |
Trailing Annual Dividend Yield | 0.00% |
Forward Annual Dividend Rate | 0.00 |
Forward Annual Dividend Yield | 0.00% |
5-Year Dividend Payments Count | 0 |
3-Year Average Dividend Yield | 0.00% |
5-Year Average Dividend Yield | 0.00% |
1-Year Dividend Growth Rate Percentage | 0.00% |
3-Year Dividend Growth Rate Percentage | 0.00% |
5-Year Dividend Growth Rate Percentage | 0.00% |
All-Time Dividend Growth Rate Percentage | 0.00% |
Dividend Payout Ratio | N/A |
Income Statement |
|
Quarterly Earnings Growth YOY | 0.00% |
Annual Earnings Growth | -189.45% |
Reported EPS 12 Trailing Months | -7.94 |
Reported EPS Past Year | -3.78 |
Reported EPS Prior Year | -5.39 |
Net Income Twelve Trailing Months | -305,348,000 |
Net Income Past Year | -106,806,000 |
Net Income Prior Year | -36,900,000 |
Quarterly Revenue Growth YOY | -18.40% |
5-Year Revenue Growth | 0.00% |
Operating Margin Twelve Trailing Months | -15.06 |
Balance Sheet |
|
Total Cash Most Recent Quarter | 240,168,000 |
Total Cash Past Year | 138,142,000 |
Total Cash Prior Year | 20,323,000 |
Net Cash Position Most Recent Quarter | 240,168,000 |
Net Cash Position Past Year | 137,642,000 |
Long Term Debt Past Year | 500,000 |
Long Term Debt Prior Year | 500,000 |
Total Debt Most Recent Quarter | 0 |
Equity to Debt Ratio Past Year | 1.00 |
Equity to Debt Ratio Most Recent Quarter | 1.00 |
Total Stockholder Equity Past Year | 119,882,000 |
Total Stockholder Equity Prior Year | 16,653,000 |
Total Stockholder Equity Most Recent Quarter | 214,906,000 |
Free Cash Flow |
|
Free Cash Flow Twelve Trailing Months | -92,589,000 |
Free Cash Flow Per Share Twelve Trailing Months | -1.48 |
Free Cash Flow Past Year | -8,399,000 |
Free Cash Flow Prior Year | -28,938,000 |
Options |
|
Put/Call Ratio | 2.78 |
Has Options | Options Chain |
Liquidity Rating | |
Technical Analysis |
|
Yahoo Finance Chart | Yahoo Finance Chart |
MACD | -0.37 |
MACD Signal | -0.23 |
20-Day Bollinger Lower Band | 9.78 |
20-Day Bollinger Middle Band | 13.34 |
20-Day Bollinger Upper Band | 16.89 |
Beta | 1.82 |
RSI | 30.09 |
50-Day SMA | 15.55 |
150-Day SMA | 8.92 |
200-Day SMA | 11.92 |
System |
|
Modified | 11/21/2024 3:43:01 AM EST |